Revenue: As of FY2026 Q1, the actual value is USD 0.

EPS: As of FY2026 Q1, the actual value is USD -0.11, beating the estimate of USD -0.1457.

Cash and Investment Position

Cash, cash equivalents, restricted cash, and available-for-sale investments were $68,318 thousand as of March 31, 2026, compared to $80,922 thousand as of December 31, 2025.

Operating Expenses

Research and development expenses were $7,317 thousand for the first quarter of 2026, a decrease from $11,814 thousand for the first quarter of 2025.General and administrative expenses were $4,119 thousand for the first quarter of 2026, an increase from $3,959 thousand for the first quarter of 2025.Total operating expenses were $11,436 thousand for the first quarter of 2026, down from $15,773 thousand for the first quarter of 2025.

Operational Metrics

Loss from operations was - $11,436 thousand for the first quarter of 2026, an improvement from - $15,773 thousand for the first quarter of 2025.Total other income (expense), net, was $644 thousand for the first quarter of 2026, compared to $892 thousand for the first quarter of 2025.Consolidated net loss was - $10,792 thousand for the first quarter of 2026, an improvement from - $14,881 thousand for the first quarter of 2025.Net loss attributable to aTyr Pharma, Inc. was - $10,791 thousand for the first quarter of 2026, an improvement from - $14,880 thousand for the first quarter of 2025.

Balance Sheet Highlights

Total assets were $79,654 thousand as of March 31, 2026, compared to $93,003 thousand as of December 31, 2025.Total stockholders’ equity was $57,741 thousand as of March 31, 2026, compared to $67,288 thousand as of December 31, 2025.

Outlook / Guidance

aTyr Pharma, Inc. plans to submit an Investigational New Drug (IND) application in June 2026 for a new Phase 3 study of efzofitimod for pulmonary sarcoidosis, using Forced Vital Capacity (FVC) as the primary endpoint and King’s Sarcoidosis Questionnaire (KSQ)-Lung score as a key secondary endpoint.The company is also on track to complete enrollment in the Phase 2 EFZO-CONNECT™ study of efzofitimod in SSc-ILD in the first half of 2026.